Literature DB >> 11145494

Production of low-avidity antibody by infants after infection with serogroup B meningococci.

A J Pollard, M Levin.   

Abstract

Experimental serogroup B meningococcal vaccines have induced only poor immune responses and have had little protective efficacy in children younger than 1 year of age. We used ELISA with potassium thiocyanate to compare the average avidity of antibody produced by infants with that of children older than 10 years after systemic disease. Infants produced specific antibody of lower average avidity than older children--a finding that correlates with absence of serum bactericidal activity in the serum samples of the same infants.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145494     DOI: 10.1016/S0140-6736(00)03405-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Improved method to calculate the antibody avidity index.

Authors:  C T Perciani; P S Peixoto; W O Dias; F S Kubrusly; M M Tanizaki
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

2.  Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans.

Authors:  M Nadeem Khan; Michael E Pichichero
Journal:  Vaccine       Date:  2012-02-17       Impact factor: 3.641

3.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

4.  Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Authors:  C L Vermont; H H van Dijken; C J P van Limpt; R de Groot; L van Alphen; G P J M van Den Dobbelsteen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Antibody response to Haemophilus influenzae outer membrane protein D, P6, and OMP26 after nasopharyngeal colonization and acute otitis media in children.

Authors:  Michael E Pichichero; Ravinder Kaur; Janet R Casey; Albert Sabirov; M Nadeem Khan; Anthony Almudevar
Journal:  Vaccine       Date:  2010-08-26       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.